Buchumschlag

Letter: Clarifying the Synergistic Mechanisms of Mediterranean Diet and Time‐Restricted Feeding in MASLD Management—Authors' Reply

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Sofia Tsitsou, Magdalini Adamantou, Triada Bali, Aristi Saridaki, Kalliopi‐Anna Poulia, Dimitrios S. Karagiannakis, Emilia Papakonstantinou, Evangelos Cholongitas
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations. Authors' Reply
von: Mohamed El‐Kassas, et al.
Veröffentlicht: (2025)

Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply
von: Yewan Park, et al.
Veröffentlicht: (2024)

Editorial: Chrononutrition and MASLD—Its About Time (Restricted Feeding)!
von: Hannah Mohr, et al.
Veröffentlicht: (2025)

Letter: Algorithmic NIT approaches to identify advanced liver fibrosis in patients with MASLD: Authors' reply
von: Stuart McPherson, et al.
Veröffentlicht: (2024)

Letter: Toward Intra‐Class Switching With JAK Inhibitors? Authors' Reply
von: Shintaro Akiyama, et al.
Veröffentlicht: (2025)

Letter: Therapeutic Targeting of PPARs in PBC —Additional Considerations. Authors' Reply
von: J. M. Schattenberg, et al.
Veröffentlicht: (2026)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
von: Virginia Solitano, et al.
Veröffentlicht: (2024)

Letter: Helicobacter pylori and Eosinophilic Oesophagitis—Lost in Definition? Authors' Reply
von: Irene Spinelli, et al.
Veröffentlicht: (2025)

Letter: Predictors of Corticosteroid Response in Alcohol‐Related Hepatitis—Authors' Reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
von: Nina Dominik, et al.
Veröffentlicht: (2024)

Mortality of Acute Kidney Injury in Cirrhosis: A Systematic Review and Meta‐Analysis of Over 5 Million Patients Across Different Clinical Settings
von: Vasileios Lekakis, et al.
Veröffentlicht: (2024)

Letter: Double PBC ‐Related Autoantibody Positivity—How Essential Is It for Diagnosis? Authors' Reply
von: Hong‐Li Liu, et al.
Veröffentlicht: (2026)

Letter: Beyond Association—Operationalising PRS ‐5 for Hepatocellular Carcinoma Surveillance. Authors' Reply
von: Yu‐Sheng Lin, et al.
Veröffentlicht: (2026)

Letter: Amino Acid Imbalance and Mortality in Cirrhosis—Interpretation and Methodological Considerations. Authors' Reply
von: Yuki Utakata, et al.
Veröffentlicht: (2026)

Letter: Enhancing Risk‐Adapted Colorectal Cancer Screening for People With Diabetes—Authors' Reply
von: Teresa Seum, et al.
Veröffentlicht: (2025)

Editorial: Understanding How Social Determinants of Health Impact Mortality in MASLD —Insights From a National Analysis. Authors' Reply
von: Donghee Kim, et al.
Veröffentlicht: (2025)

Editorial: Beyond Clinical Trials—Real‐World Data Suggest Usefulness of GLP‐1 RAs in MASLD Treatment. Authors' Reply
von: Chia‐Chih Kuo, et al.
Veröffentlicht: (2025)

Letter: Drug‐Induced Autoimmune‐Like Hepatitis—A Trigger on the Disease Spectrum. Authors' Reply
von: Pinelopi Arvaniti, et al.
Veröffentlicht: (2025)

Letter: Addressing Gaps in Hospital‐Based Hepatitis C Screening—Insights and Recommendations. Authors' Reply'
von: Alberto Ferrarese, et al.
Veröffentlicht: (2025)

Letter on ‘Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis’: Authors' Reply
von: Lukas Burghart, et al.
Veröffentlicht: (2026)

Letter: Are Antispasmodics Truly Ineffective in IBD? Considerations on Nuanced Interpretation and Stratified Analysis. Authors' Reply
von: Chachrit Khunsriraksakul, et al.
Veröffentlicht: (2025)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
von: Juan Macias, et al.
Veröffentlicht: (2025)

Editorial: Can We Modify the Development and Disease Course of Inflammatory Bowel Disease by Diet? Author's Reply
von: Aurelien Amiot, et al.
Veröffentlicht: (2025)

Letter: Methodological Considerations in Interpreting Polygenic Risk Scores for Hepatocellular Carcinoma After SVR . Authors' Reply
von: Yu‐Sheng Lin, et al.
Veröffentlicht: (2026)

Letter: Thiopurines the Silent Workhorse for Many Patients After a Flare of Ulcerative Colitis. Authors' Reply
von: Ankit Kumar, et al.
Veröffentlicht: (2026)

Letter: Meta‐Analysis: Prevalence of Frailty and Associated Adverse Events in Inflammatory Bowel Disease—Authors' Reply
von: Isabel Carbery, et al.
Veröffentlicht: (2024)

Letter: Allostatic Load and Adverse Prognosis in Inflammatory Bowel Disease—Need More Evidence. Authors' Reply
von: Jianhui Zhao, et al.
Veröffentlicht: (2024)

Letter on ‘Meta‐Analysis: Mortality Trends and Risk Factors in Severe Alcohol‐Associated Hepatitis’—Authors' Reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
von: Christian Labenz, et al.
Veröffentlicht: (2026)

Letter: From Regional Diagnostic Thresholds to Phenotype‐Guided Management in Asian Reflux Disease. Authors' Reply
von: Walter W. Chan, et al.
Veröffentlicht: (2026)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply
von: Eunice Yewon Lee, et al.
Veröffentlicht: (2024)

Letter: Incremental Value and Stratified Interpretation of Dual Autoantibody Positivity in Primary Biliary Cholangitis. Authors' Reply
von: Hong‐Li Liu, et al.
Veröffentlicht: (2026)

Letter: Peripheral Eosinophilia Does Not Correlate With Endoscopic and Histological Activity in Paediatric Eosinophilic Oesophagitis. Authors' Reply
von: Pierfrancesco Visaggi, et al.
Veröffentlicht: (2026)

Letter: Is Enteric Neuropathy Absent in Hypermobility Spectrum Disorders/Hypermobile Ehler–Danlos Syndrome? Authors' Reply
von: Kim W. E. Sweerts, et al.
Veröffentlicht: (2025)

Letter: No Biochemical Relapse Is Associated With the Highest Off‐Therapy HBsAg Loss Rate—Authors' Reply
von: Ying‐Nan Tsai, et al.
Veröffentlicht: (2025)

Letter: Methodological Gaps Undermine Conclusions on Electronic Nose Use for Colorectal Cancer Detection—Authors' Reply
von: Milou. L. M. van Riswijk, et al.
Veröffentlicht: (2025)

Letter: Lubiprostone Treatment for MASLD—Gender Imbalance and Blinding Considerations
von: Jiru Li, et al.
Veröffentlicht: (2025)

Editorial: Food for Thought—Addressing the Nuances of Diet and Mood When Evaluating Dietary Intervention in IBS. Authors' Reply
von: Anthony O'Connor, et al.
Veröffentlicht: (2024)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
von: Kaleb Tesfai, et al.
Veröffentlicht: (2026)

Letter: Enhancing Predictive Models for Paediatric Ulcerative Colitis—Addressing Socioeconomic, Environmental and Clinical Factors. Authors' Reply
von: Merle Claßen, et al.
Veröffentlicht: (2024)